Wells Fargo
ALGS icon

Wells Fargo’s Aligos Therapeutics ALGS Stock Holding History

Wells Fargo’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.2K Sell
700
-800
-53% -$6.07K ﹤0.01% 6109
2025
Q4 		$14K Sell
1,500
-1,670
-53% -$15.8K ﹤0.01% 5879
2025
Q3 		$31.1K Sell
3,170
-10,600
-77% -$96.9K ﹤0.01% 5687
2025
Q2 		$99.3K Sell
13,770
-9,260
-40% -$55.4K ﹤0.01% 5197
2025
Q1 		$190K Buy
23,030
+1,230
+6% +$27K ﹤0.01% 4744
2024
Q4 		$869K Buy
+21,800
New +$421K ﹤0.01% 3803
2024
Q2 		– Sell
-12
Closed -$292 – 6882
2024
Q1 		$292 Hold
12
– – ﹤0.01% 6409
2023
Q4 		$195 Buy
12
+4
+50% +$69 ﹤0.01% 6617
2023
Q3 		$146 Hold
8
– – ﹤0.01% 6660
2023
Q2 		$192 Buy
8
+1
+14% +$27 ﹤0.01% 6716
2023
Q1 		$154 Hold
7
– – ﹤0.01% 6841
2022
Q4 		$165 Hold
7
– – ﹤0.01% 6676
2022
Q3 		$0 Buy
7
+2
+40% +$66 ﹤0.01% 6608
2022
Q2 		$0 Sell
5
-37
-88% -$1.26K ﹤0.01% 6749
2022
Q1 		$2K Sell
42
-301
-88% -$24.1K ﹤0.01% 6642
2021
Q4 		$101K Buy
+343
New +$125K ﹤0.01% 5629
2021
Q2 		– Sell
-131
Closed -$74K – 6858
2021
Q1 		$74K Sell
131
-79
-38% -$52.6K ﹤0.01% 5619
2020
Q4 		$145K Buy
+210
New +$102K ﹤0.01% 5211

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wells Fargo's ALGS Position: Q1 2026 in Review

Wells Fargo reduced its Aligos Therapeutics (ALGS) stake by 53% in Q1 2026, selling an estimated $6.07K and leaving 700 shares worth $5.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6109.

Wells Fargo first reported a position in ALGS in Q4 2020 and has held it in 18 quarters since. The position peaked at $869K in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Wells Fargo held 700 shares of Aligos Therapeutics worth $5.2K as of Q1 2026.
  • Wells Fargo sold 800 Aligos Therapeutics shares in Q1 2026, an estimated $6.07K.
  • Aligos Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6109 holding.
  • Wells Fargo first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • Wells Fargo's Aligos Therapeutics position peaked at $869K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.